Werewolf Therapeutics Stock (NASDAQ:HOWL)
Previous Close
$1.93
52W Range
$1.66 - $8.19
50D Avg
$2.27
200D Avg
$3.91
Market Cap
$78.88M
Avg Vol (3M)
$643.48K
Beta
0.41
Div Yield
-
HOWL Company Profile
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| TALS | Tourmaline Bio, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| DBTX | Decibel Therapeutics, Inc. |
| VOR | Vor Biopharma Inc. |
| IKNA | Ikena Oncology, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| CSBR | Champions Oncology, Inc. |
| PASG | Passage Bio, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| THRD | Third Harmonic Bio, Inc. |
| MOLN | Molecular Partners AG |
| ACET | Adicet Bio, Inc. |
| CELC | Celcuity Inc. |
| ELYM | Eliem Therapeutics, Inc. |